Legal Opinion
Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd.
District Court, D. Delaware
Decided February 10, 2023No. 1:19-cv-02100Unknown
1Opinion
INTHEUNITEDSTATESDISTRICTCOURT FORTHEDISTRICTOFDELAWARE AZURITYPHARMACEUTICALS,INC., Plaintiff, CivilAction v. No. 19-cv-2100 ALKEMLABORATORIESLTD., Defendant. MEMORANDUMOPINION Goldberg,J.1 February10,2023 This lawsuit was brought under the Hatch Waxman Act for patent infringement pursuant to 35 U.S.C. § 271(e)(2)(a). Plaintiff Azurity Pharmaceuticals, Inc. (“Azurity”) claims that an Abbreviated New Drug Application (ANDA) submitted by Defendant Alkem Laboratories Ltd. (“Alkem”) infringes U.S. Patent Nos. 10,786,482 (the ’482 patent) and 10,918,621 (the ’621 patent), both titled “Enalapril…
2Cases cited26 opinions
- KSR International Co. v. Teleflex Inc.Supreme Court of the United States · 2007
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Sri International v. Matsushita Electric Corporation of America and Matsushita Electric Industrial Co., Ltd.Court of Appeals for the Federal Circuit · 1985
- Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.Court of Appeals for the Federal Circuit · 2010
- Pfizer, Inc. v. Apotex, Inc.Court of Appeals for the Federal Circuit · 2007
21 more not listed; retrieve them via the Exa API.